Retinal degeneration
MONDO:0004580Degeneration of the retina.
Also known as: retina degeneration, retina, Degeneration Of
586 clinical trials for this condition and its sub-types, 41 tagged with Retinal degeneration itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Retinal degeneration
-
Inherited retinal dystrophy 41 trials · 513 incl. sub-types
105 sub-types
- Age-related macular degeneration 190 trials · 334 incl. sub-types Sub-types →
- Retinitis pigmentosa 84 trials · 89 incl. sub-types Sub-types →
- Hereditary macular dystrophy 3 trials · 72 incl. sub-types Sub-types →
- Cone-rod dystrophy 17 trials · 21 incl. sub-types Sub-types →
- ABCA4-related retinopathy 7 trials · 13 incl. sub-types Sub-types →
- Leber congenital amaurosis 11 trials · 13 incl. sub-types Sub-types →
- RPE65-related recessive retinopathy 5 trials · 8 incl. sub-types Sub-types →
- BEST1-related dominant retinopathy 1 trial · 7 incl. sub-types Sub-types →
- RHO-related retinopathy 0 trials · 7 incl. sub-types Sub-types →
- RPGR-related retinopathy 0 trials · 7 incl. sub-types Sub-types →
- Choroideremia 6 trials Sub-types →
- PRPF31-related retinopathy 1 trial · 4 incl. sub-types Sub-types →
- X-linked retinoschisis 4 trials
- Ornithine aminotransferase deficiency 4 trials
- ELOVL4-related maculopathy 0 trials · 3 incl. sub-types Sub-types →
- RLBP1-related retinopathy 2 trials · 3 incl. sub-types Sub-types →
- Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 3 trials
- BEST1-related recessive retinopathy 0 trials · 2 incl. sub-types Sub-types →
- EYS-related retinopathy 1 trial · 2 incl. sub-types Sub-types →
- LCA5-related retinopathy 1 trial · 2 incl. sub-types Sub-types →
- PRPH2-related retinopathy 1 trial · 2 incl. sub-types Sub-types →
- Revesz syndrome 2 trials
- Late-onset retinal degeneration 2 trials
- AIPL1-related retinopathy 1 trial Sub-types →
- ATF6-related retinopathy 0 trials · 1 incl. sub-types Sub-types →
- CNGB1-related retinopathy 0 trials · 1 incl. sub-types Sub-types →
- FLVCR1-related retinopathy with or without ataxia 0 trials · 1 incl. sub-types Sub-types →
- GUCY2D retinopathy 0 trials · 1 incl. sub-types Sub-types →
- RDH5-related retinopathy 0 trials · 1 incl. sub-types Sub-types →
- Retinoschisis of fovea 1 trial
- ADAM9-related retinopathy 0 trials Sub-types →
- CACNA1F-related retinopathy 0 trials Sub-types →
- CACNA2D4-related retinopathy 0 trials Sub-types →
- CDHR1-related retinopathy 0 trials Sub-types →
- CERKL-related retinopathy 0 trials Sub-types →
- CNGA1-related retinopathy 0 trials Sub-types →
- CNGA3-related retinopathy 0 trials Sub-types →
- CRX-related retinopathy 0 trials Sub-types →
- GNAT2-related retinopathy 0 trials Sub-types →
- GPR179-related retinopathy 0 trials Sub-types →
- GRM6-related retinopathy 0 trials Sub-types →
- GUCA1A-related retinopathy 0 trials Sub-types →
- HGSNAT-related retinopathy 0 trials Sub-types →
- IDH3B-related retinopathy 0 trials Sub-types →
- IMPDH1-related retinopathy 0 trials Sub-types →
- IMPG1-related dominant retinopathy 0 trials Sub-types →
- IMPG1-related recessive retinopathy 0 trials Sub-types →
- IMPG2-related dominant retinopathy 0 trials Sub-types →
- IMPG2-related recessive retinopathy 0 trials Sub-types →
- KCNV2-related retinopathy 0 trials Sub-types →
- KIZ-related retinopathy 0 trials Sub-types →
- LRIT3-related retinopathy 0 trials Sub-types →
- MAK-related retinopathy 0 trials Sub-types →
- MERTK-related retinopathy 0 trials Sub-types →
- MRCS syndrome 0 trials
- NMNAT1-related retinopathy 0 trials Sub-types →
- NYX-related retinopathy 0 trials Sub-types →
- Oguchi disease 0 trials Sub-types →
- PCARE-related retinopathy 0 trials Sub-types →
- PDE6A-related retinopathy 0 trials Sub-types →
- PDE6C-related retinopathy 0 trials Sub-types →
- PDE6G-related retinopathy 0 trials Sub-types →
- PROM1-related retinopathy 0 trials Sub-types →
- PRPF8-related retinopathy 0 trials Sub-types →
- RAB28-related retinopathy 0 trials Sub-types →
- RD3-related retinopathy 0 trials Sub-types →
- RDH12-related dominant retinopathy 0 trials
- RDH12-related recessive retinopathy 0 trials Sub-types →
- REEP6-related retinopathy 0 trials Sub-types →
- RP1-related dominant retinopathy 0 trials
- RP1-related recessive retinopathy 0 trials
- RP2-related retinopathy 0 trials Sub-types →
- RPE65-related dominant retinopathy 0 trials Sub-types →
- SNRNP200-related dominant retinopathy 0 trials Sub-types →
- SPATA7-related retinopathy 0 trials Sub-types →
- Sorsby fundus dystrophy 0 trials Sub-types →
- TOPORS-related retinopathy 0 trials Sub-types →
- TRPM1-related retinopathy 0 trials Sub-types →
- TTLL5-related retinopathy 0 trials Sub-types →
- X-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 0 trials
- X-linked retinal dysplasia 0 trials
- Aceruloplasminemia 0 trials
- Amaurosis-hypertrichosis syndrome 0 trials
- Choroideremia-deafness-obesity syndrome 0 trials
- Dystrophies primarily involving the retinal pigment epithelium 0 trials
- Ectopia lentis-chorioretinal dystrophy-myopia syndrome 0 trials
- Familial benign flecked retina 0 trials
- Foveal hypoplasia-presenile cataract syndrome 0 trials
- Helicoid peripapillary chorioretinal degeneration 0 trials
- Infantile cerebellar-retinal degeneration 0 trials
- Macular degeneration, early-onset 0 trials
- Microcephaly and chorioretinopathy 1 0 trials
- Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability 0 trials
- Microcornea-myopic chorioretinal atrophy 0 trials
- Oligocone trichromacy 0 trials
- Pigmented paravenous retinochoroidal atrophy 0 trials
- Progressive bifocal chorioretinal atrophy 0 trials
- Progressive retinal dystrophy due to retinol transport defect 0 trials
- Retinal degeneration-nanophthalmos-glaucoma syndrome 0 trials
- Retinal dystrophies primarily involving Bruch's membrane 0 trials Sub-types →
- Retinal dystrophy in systemic or cerebroretinal lipidoses 0 trials
- Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies 0 trials
- Retinal dystrophy, X-linked, Gardner-Hardcastle type 0 trials
- Retinoschisis, autosomal dominant 0 trials
- Vitreoretinal dystrophy 0 trials
-
Macular degeneration 212 trials · 429 incl. sub-types
9 sub-types
- Degeneration of macula and posterior pole 0 trials · 354 incl. sub-types Sub-types →
- Stargardt disease 35 trials · 36 incl. sub-types Sub-types →
- Macular retinal edema 20 trials · 28 incl. sub-types Sub-types →
- Vitelliform macular dystrophy 6 trials · 10 incl. sub-types Sub-types →
- Autosomal recessive bestrophinopathy 2 trials
- Isolated macular dystrophy 0 trials
- Macular degeneration, early-onset 0 trials
- Occult macular dystrophy 0 trials
- Patterned macular dystrophy 0 trials Sub-types →
-
Retinoschisis 5 trials · 6 incl. sub-types
5 sub-types
- X-linked retinoschisis 4 trials
- Retinoschisis of fovea 1 trial
- Bullous retinoschisis 0 trials
- Flat retinoschisis 0 trials
- Retinoschisis, autosomal dominant 0 trials
-
Peripheral retinal degeneration 1 trial · 2 incl. sub-types
6 sub-types
- Retinal lattice degeneration 1 trial
- Blessig's cysts 0 trials
- Cobblestone retinal degeneration 0 trials
- Pseudoretinitis pigmentosa 0 trials
- Secondary vitreoretinal degeneration 0 trials
- Senile reticular retinal degeneration 0 trials
-
Cone dystrophy 1, X-linked 0 trials
-
Cone dystrophy 5, X-linked 0 trials
Most studied deeper sub-types
-
Gene therapy shot could end frequent eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged…
Phase 1/2 • Sponsor: Elisigen, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a common diabetes drug protect eyesight in stargardt disease?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, can safely slow vision loss in people with ABCA4 retinopathy (Stargardt disease). Fifty-five participants aged 12 and older will take metformin by mouth for 24 months, with regular eye exams to track changes. The go…
Phase 1/2 • Sponsor: National Eye Institute (NEI) • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can an arthritis drug save sight? small trial tests adalimumab for rare eye diseases
Disease control OngoingThis pilot study tests whether adalimumab, an anti-inflammatory drug, can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants will receive three injections into the eye over four months. The main goal is to see if the t…
Phase 1/2 • Sponsor: Centro de Pesquisa Rubens Siqueira • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Gene therapy shot into both eyes aims to save sight in rare blindness
Disease control OngoingThis study tests a gene therapy called laruparetigene zovaparvovec (AGTC-501) in 10 males aged 12-50 with X-linked retinitis pigmentosa, a genetic condition that leads to vision loss. The therapy is injected into both eyes to deliver a working copy of the RPGR gene. The main goal…
Phase 2 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MS drug may shield eyes from damage, new study hopes to prove
Disease control By invitation onlyThis study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental eye drug shows promise for rare Blindness-Causing disease
Disease control OngoingThis study tests an experimental drug called VP-001 for people with a rare genetic eye disease that causes vision loss. The drug is injected into the eye and aims to slow or stop further damage. Researchers will check safety and measure any changes in eyesight over about two year…
Phase 1/2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
One-Time eye injection could slow blindness in retinitis pigmentosa
Disease control OngoingThis study tests a gene therapy called SPVN06 for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment is given as a single injection under the retina. The trial includes 33 adults with advanced disease and will check safety and whether it…
Phase 1/2 • Sponsor: SparingVision • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Gene therapy offers hope for rare Blindness-Causing eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive one of two doses of the therapy or no treatment, and researchers measure changes in vision under low ligh…
Phase 2/3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
Disease control OngoingThis early-stage trial tests a combination treatment for retinitis pigmentosa, a genetic disease that causes blindness. Ten adults receive a single injection of GS030 gene therapy into one eye, then use special glasses that send light signals to the treated retina. The main goal …
Phase 1/2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy for wet AMD: could this mean fewer eye injections?
Disease control OngoingThis study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the n…
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New eye tests could speed up retinitis pigmentosa treatment trials
Knowledge-focused OngoingThis study aims to find better ways to measure how retinitis pigmentosa (a genetic eye disease that causes vision loss) progresses over time. Researchers will use advanced imaging and vision tests in 40 people with specific genetic forms of the disease. The goal is to identify re…
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists map rare blindness to speed future cures
Knowledge-focused OngoingThis study follows 44 people with a rare genetic form of Usher syndrome caused by PCDH15 mutations. Over 48 months, researchers measure how their vision changes using eye exams and imaging. The goal is to identify the best ways to track disease progression, which will help design…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Could a workout save your sight? new study investigates
Knowledge-focused OngoingThis study aims to find out if changes in blood markers can predict whether exercise helps improve vision. Researchers will compare aerobic exercise to balance training in 14 sedentary adults aged 18 to 89 with vision disorders. The goal is to understand how exercise might protec…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC